Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 265,876 | 7,020 | N/A | N/A |
| Other current assets | 0 | 1,526 | 0 | 0 |
| TOTAL | $267,726 | $8,927 | $N/A | $N/A |
| Non-Current Assets | ||||
| PPE Net | 724 | 708 | N/A | N/A |
| Other Non-Current Assets | 993 | 1,320 | 0 | 0 |
| TOTAL | $1,717 | $2,028 | $N/A | $N/A |
| Total Assets | $269,443 | $10,955 | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 2,149 | 2,088 | 0 | 0 |
| Accrued Expenses | 4,612 | 2,022 | N/A | N/A |
| TOTAL | $7,184 | $4,486 | $N/A | $N/A |
| Non-Current Liabilities | ||||
| Other Non-Current Liabilities | 538 | 5,974 | 0 | 0 |
| TOTAL | $538 | $5,974 | $N/A | $N/A |
| Total Liabilities | $7,722 | $10,460 | $N/A | $N/A |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 23,271 | N/A | N/A | N/A |
| Common Shares | 2 | 1 | N/A | N/A |
| Retained earnings | -65,011 | -19,650 | N/A | N/A |
| Other shareholders' equity | 0 | 19,941 | 0 | 0 |
| TOTAL | $261,721 | $495 | $N/A | $N/A |
| Total Liabilities And Equity | $269,443 | $10,955 | $0 | $0 |